Pembrolizumab plus CRT produced “robust and durable anti-tumor activity” in the KEYNOTE-799 trial, said Martin Reck, MD, PhD.

An EMR-based prompt significantly boosted molecular testing rates and detection of actionable mutations in early-stage, ...

OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced that three of its research abstracts have been accepted for poster ...

Discover why Genmab's antibody platforms, growing royalties, and late-stage pipeline make it a top biotech stock for ...

Artificial intelligence (AI) is now being integrated into many aspects of healthcare, helping physicians with diagnostics, ...

Special meeting of stockholders to vote on Merger to take place on May 28, 2025 WALTHAM, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint”) (Nasdaq: CKPT), a ...

Leading cancer researchers from UC San Francisco presented talks about advances in targeted therapies, cancer genomics, using AI to personalize cancer treatment, improving diagnosis of hard-to-treat ...

Methods and analysis EVOLUTION is a multicentre ... 16), used in conjunction with platinum-based agents, is a recognised treatment for both small cell and non-small cell lung cancer.2 Recent research ...

Ivonescimab represents a new, more effective, and safer "chemotherapy-free" option for the first-line treatment of NSCLC. Ivonescimab is the first bispecific antibody approved globally with a dual ...

“In lung cancer therapy, it is basically part of everyone's cancer treatment pathway to have this ... 4 that cancer cells use to evade the immune system. These drugs have shown efficacy in melanoma, ...

perspective on the evolution of targeted therapies for locally advanced or metastatic EGFR-mutated NSCLC. PFS With Amivantamab Plus Lazertinib According to the National Comprehensive Cancer Network ...